Detalhe da pesquisa
1.
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study.
Br J Haematol
; 196(3): 639-648, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34671975
2.
Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Oncologist
; 16(2): 197-206, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21273514
3.
Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
J Clin Oncol
; 39(7): 757-767, 2021 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33296242
4.
Simultaneous presentation of two distinct plasma cell neoplasms.
Proc (Bayl Univ Med Cent)
; 31(4): 514-515, 2018 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-30948996
5.
O6-benzylguanine and BCNU in multiple myeloma: a phase II trial.
Cancer Chemother Pharmacol
; 60(3): 415-21, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17354015
6.
Haematological complete remission by ponatinib and bortezomib in a patient with relapsed, Ph⺠pre-B acute lymphoblastic leukaemia.
BMJ Case Rep
; 20142014 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-24729118